July 2022 Issue


 


Money Is Not the Key to Modernizing Your Nuclear Cardiology Lab

ASNC asked stakeholders across nuclear cardiology for thoughts on tackling lab modernization. Almost everyone told us some version of “Upgrade your camera if you can but, if that’s not feasible now, you have other options.” Let's look at options for lab improvement. Many of them could pay big dividends for your patients, your practice and your field.

Article developed by ASNC
 
 

 


Putting PatientFirst Imaging Into Practice

David Wolinsky, MD, MASNC, from Cleveland Clinic, was a co-creator of ASNC's PatientFirst Imaging initiative. We asked him about the program and how nuclear labs can incorporate PatientFirst Imaging into their own practices.

Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc. ©2022 Astellas Pharma US, Inc.   All rights reserved.
014-0630-PM   07/22
Sponsored by



 




Reducing Radiation Dose in Nuclear Cardiology
By Thomas H. Hauser, MD, MPH, MMSc (@ThomasHauser_MD)

Nuclear cardiology studies play a key role in the diagnosis of heart disease, the determination of prognosis, and the appropriate management of patients. Although these benefits are clear, we must also be mindful of the potential downsides associated with these studies, including the use of ionizing radiation.
 

Article developed for ASNC
 


 


Stress Agents and Nuclear Lab Emergencies
By Brett W. Sperry, MD (@BrettSperryMD)

Understanding the stress agents used in the nuclear lab as well as potential emergencies and supply shortages is essential for providers who are involved in nuclear cardiology. While these concepts are some of the first that we learn when studying for a career in nuclear medicine, they can easily be forgotten in day-to-day practice.
 

Article developed for ASNC
 


 


Cardiac Amyloid Imaging with Tc-99m PYP: Challenges and Potential Solutions
By Vivek Singh, DO, and Renee P. Bullock-Palmer, MD, FASNC (@RBP0612)

Cardiac amyloidosis is a progressive disorder that can lead to nearly irreversible damage in the heart, typically in the form of cardiomyopathy and/or arrhythmias. It is not as uncommon as once postulated and remains a relatively underdiagnosed pathologic process. There are various challenges to keep in mind when using Tc-99m PYP as a diagnostic tool for transthyretin cardiac amyloidosis. There also are solutions. Let's examine both.
 

Article developed for ASNC